Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants

Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants

The neutralizing antibody is a potential therapeutic for the ongoing COVID-19 pandemic. As an antiviral agent, numerous mAbs recognize the epitopes that overlap with ACE2-binding sites in the SARS-CoV-2-RBD. Some studies have shown that residual changes on the spike protein can significantly decreas...

Full description

Bibliographic Details
Main Authors: Fengze Wang, Li Li, Yang Dou, Rui Shi, Xiaomin Duan, Hongchuan Liu, Jing Zhang, DanDan Liu, Jing Wu, Yang He, Jun Lan, Bai Lu, Hui Feng, Jinghua Yan
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Emerging Microbes and Infections
Subjects:
sars-cov-2
etesevimab
js026
antibody cocktail
variants of concern
Online Access:http://dx.doi.org/10.1080/22221751.2022.2032374

Internet

http://dx.doi.org/10.1080/22221751.2022.2032374

Similar Items